In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As ...

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS increase.

Abbott Laboratories’ ABT growth in the fourth quarter ... the company is driving robust growth through its flagship, sensor-based CGM system — FreeStyle Libre. However, a dull macroeconomic ...

Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...

This series of continuous glucose monitoring (CGM ... then, look safe. Abbott Laboratories has increased its payouts for 52 consecutive years and currently offers a forward yield of 2%.

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc., Abbott Laboratories and ... Lingo and Libre Rio CGM devices are on a great trajectory.